{
  "title": "Paper_1015",
  "abstract": "pmc Pharmaceuticals (Basel) Pharmaceuticals (Basel) 2102 pharmaceuticals pharmaceuticals Pharmaceuticals 1424-8247 Multidisciplinary Digital Publishing Institute  (MDPI) PMC12472391 PMC12472391.1 12472391 12472391 41011173 10.3390/ph18091302 pharmaceuticals-18-01302 1 Article Borylated Five-Membered Ring Iminosugars: Synthesis, Spectroscopic Analysis, and Biological Evaluation for Glycosidase Inhibition and Anticancer Properties for Application in Boron Neutron Capture Therapy (BNCT)—Part 1 Prichard Kate Validation 1 Yamamoto Suzuka Investigation 2 Shimadate Yuna Investigation 2 Yoshimura Kosuke Investigation 2 Bartholomew Barbara Investigation 3 https://orcid.org/0000-0001-5034-386X Gilbert Jayne Investigation 4 https://orcid.org/0000-0002-7009-5792 Sakoff Jennette Investigation 4 https://orcid.org/0000-0002-3272-640X Nash Robert Investigation 3 https://orcid.org/0000-0001-8022-196X Kato Atsushi Investigation 2 https://orcid.org/0000-0002-1339-8236 Simone Michela Conceptualization Methodology Writing – original draft Supervision Project administration Funding acquisition 1 5 * Imperio Daniela Academic Editor Panza Luigi Academic Editor 1 2 kato@med.u-toyama.ac.jp 3 robert.nash@phytoquest.co.uk 4 jennette.sakoff@newcastle.edu.au 5 * michela_simone@yahoo.co.uk 29 8 2025 9 2025 18 9 497460 1302 22 4 2025 18 8 2025 20 8 2025 29 08 2025 27 09 2025 29 09 2025 © 2025 by the authors. 2025 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/ Background/Objectives N Methods: Results: 50 d d Conclusions: monosaccharide iminosugar boronic acid boronate boron BNCT glycosidase cancer Fsp 3 NMR mutarotation borarotation induced fit the University of Newcastle—by the Priority Research Centre for Drug Development and by the Faculty of Science B18 JST SPRING JPMJSP2145 Financial support for this project provided by the B18 Project and—at the University of Newcastle—by the Priority Research Centre for Drug Development and by the Faculty of Science is gratefully acknowledged. Many thanks to M. Rossignoli at the University of Newcastle for NMR instrumentation support, and to I. van Altena and X. Quiñones Géldrez for useful discussions. This work was supported by JST SPRING (Grant Number JPMJSP2145) (K.Y.). pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes 1. Introduction Introduction of organic boron pharmacophores on biologically active molecules provides the opportunity to expand the profile of interactions between ligand and enzyme, and lower the toxicity of drug leads of high potency. Iminosugars are an important family of high Fsp 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 N 30 31 21 22 23 24 25 26 27 28 30 24 32 The chemistry of iminosugars is rich, and the chemical space traditionally occupied by medicinal chemistry is greatly expanded through carbohydrate analogues [ 16 33 34 35 36 37 38 39 40 41 42 43 3 1 l gulo 3 44 45 Inclusion of organic boron pharmacophores in our carbohydrate chemistry [ 46 47 22 47 48 49 50 51 An organic B atom, in the form of a trigonal planar boronic acid or boronate ester, in a molecule can reversibly form dative bonds with nucleophilic atoms located intramolecularly and/or intermolecularly. These interactions give rise to borarotation, the equilibrium of trigonal planar and tetrahedral boron species. The final equilibrium mixture depends on several factors, including pH, solvent, temperature, concentration, arrangement of atoms in space, and intramolecular proximity of nucleophilic atoms [ 47 51 52 Here, we communicate the synthesis of two families of five-membered ring iminosugars (of which one is borylated) of l gulo 3 33 47 48 49 51 53 54 55 2. Results and Discussion 2.1. Synthesis The first four synthetic steps employed a protocol available from the literature to divergent intermediate 2 56 O d 1 2 Scheme 1 O d 289 19 O d 289 24 3 56 D 20 3 56 O O p d O d p 2 289 24 2 56 D 20 2 56 2 The N 57 N 2 N The final optimised method uses a slight excess of the iminosugar starting material (1.1 eq.) compared to the base K 2 3 3 para 6 The deprotection conditions to give the corresponding lactol were optimised using HCl (aq. 1.0 M) at temperatures which varied depending on the benzyl substitution. The deprotection of the benzylated compound 3 para 6 The final reduction step to give the target compounds 5 para 8 4 para 7 5 4 4 para 8 4 4 2.2. 11 The borarotation process occurs for borylated species para 6 para 7, para 8 Figure 1 11 para 6 para 7, para 8 38 39 40 para 7 Table 1 The 11 para 6 para 7 para 8 para 7 para 6 para 8 p para 8 para 6 In para 6 3 para 7 α-fur β-fur para 7 α-fur β-fur 2 para 8 pharmaceuticals-18-01302-t001_Table 1 Table 1 11 para meta ortho para 7 meta 3 ortho 3 51 tet trig Compound Chemical Shifts Compound Chemical Shifts Compound Chemical Shifts  Signal Integration Signal Integration Signal Integration  Signal Shape Signal Shape Signal Shape  Geometry Geometry Geometry  para 6 3 30.6 22.3 meta 2 3 30.8 ortho 2 3 31.0 22.3  3.7 1.0 NA 6.4 1.0  broad sharp Broad sharp sharp  Boronate ester trig Boronate tet Boronate ester trig Boronate trig Boronate tet  para 7 2 α-fur/β-fur 28.7 19.4 meta 3 2 α-fur/β-fur 28.6 19.2 ortho 3 2 α-fur:β-fur 28.0 19.3  9.3 1.0 6.5 1.0 4.0 1.0  broad sharp broad sharp broad sharp  Boronic acid trig Boronate tet Boronic acid trig Boronate tet Boronic acid trig Boronate tet  para 8 2 28.0 19.3 meta 4 2 27.8 19.3 ortho 4 2  28.3 19.4 12.3, 11.0 3.9 1.0 1.7 1.0  1.1 6.1 1.2, 1.0 broad sharp broad sharp  broad sharp Sharp, merging Boronic acid trig Boronate tet Boronic acid trig Boronate tet  Boronic acid (trig) Boronate (partially tet ( tet  meta 5 28.6 18.6 ortho 5 2 29.5 19.3  8.6 1.0 4.5 1.0  sharp sharp broad sharp  Boronic acid trig Boronate tet Boronic acid trig Boronate tet  The signals for trigonal planar B atoms tend to be broad, and those for partially tetrahedral/tetrahedral B atoms are significantly sharper. The broadness of the trigonal planar B atoms introduces a certain degree of error in the estimation of the borarotated composition. It is nonetheless important to estimate these ratios for application purposes. 2.3. Observations on NMR Features for Borylated and Non-Borylated Compounds 2.3.1. Signal Broadening in the 13 Table 2 Table 3 There are signal broadening effects in 13 The ArC quat para 6 para 7 para 8 Lactols 4 para 7 Table 3 58 59 60 61 62 ring-opening/-closing tautomerism Hydrogen bonding. Intramolecular or intermolecular hydrogen bonding in lactols can also influence relaxation times and contribute to line broadening. Conformational exchanges. The cyclic structure of lactols can adopt multiple conformations, causing additional dynamic averaging of carbon signals. These processes cause the carbon nuclei to experience different chemical environments on the NMR timescale (10 2 4 −1 Most of the studies in this area present in the scientific literature relate to 1 13 63 13 pharmaceuticals-18-01302-t002_Table 2 Table 2 Comparison of selected 1 N 3 5 para 6 para 8 2 J   Compound: 1,4-Dideoxy-1,4-Imino-  1 J  H-1  H-1′  H-2  H-3  H-4  H-5  H-6  H-6′  ArCH 2  ArCHs N d 64 3.51, dd J δ 3.28, m 4.42, app-s δ 4.24, m δ 3.58, dd J δ 4.24, m δ 3.40, m δ 3.28, m δ 3.40, m δ 7.37, m N d 3 65 δ 2.86, m δ 2.71, dd J H-1′,H-1 J H-1′,H-2 δ 3.95–3.84, δ 4.09, m δ 2.91, dd J H-4,H-5 J H-4,H-3 δ 3.95–3.84, δ 3.72, dd J H-6,H-6′ J H-6,H-5 δ 3.68, dd J H-6′,H-6 J H-6′,H-5 δ 4.20, d J δ J δ 7.39–7.20, m N d 64 δ 3.27, d J H-1,H-1′ δ 3.71, dd J H-1′,H-1 J H-1′,H-2 δ 4.31, m δ 4.16, d δ 3.60, br s δ 3.79, m δ 3.60, br s δ 4.46, d J δ 7.37, m N O d 3 3 δ 5.99, d J H-1,H-2 NA δ 4.51, d J H-2,H-1 δ 3.26, d J H-3,H-4 δ 4.83, t J H-4,H-3/H-5 δ 4.15, app-dddd J H-5,H-6/H-4/OH J H-5,H-6′ δ 2.93, dd J H-6,H-6′ J H-6,H-5 δ 2.43, dd J H-6′,H-6 J H-6′,H-5 δ 3.95, d J Ha,Hb J Hb,Ha δ N d 4 α-fur δ 5.51, d J H-1,H-2 NA δ 4.48–4.43, δ 4.31, dd J H-3,H-4 J H-3,H-2 δ 4.98, d J δ 4.48–4.43, δ 3.66–3.60, δ 3.57, dd J H-6′,H-6 J H-6′,H-5 δ 4.57, d J Ha,Hb J Hb,Ha δ N d 4 β-fur δ 5.36, d J H-1,H-2 NA δ 4.57–4.53, δ 4.23, dd J H-3,H-4 J H-3,H-2 δ 5.00, app-d J H-4,H-3 δ 4.57–4.53, δ 3.81, dd J H-6,H-6′ J H-6,H-5 δ 3.62–3.55, δ 4.63, d J Ha,Hb J Hb,Ha δ N l 5 δ 3.59, dd J H-1,H-1′ J H-1,H-2 δ 3.28, dd J H-1′,H-1 J H-1′,H-2 δ 4.55, dddd J H-2,H-1′ J H-2,H-1/H-3 J 3.6 δ 4.42, ddd J H-3,H-2 J H-3,H-4 J 3.0 δ 3.84, dd J H-4,H-5 J H-4,H-3 δ 4.38, ddd J H-5,H-4 J H-5,H-6′ J H-5,H-6 δ 3.85, dd J H-6,H-6′ J H-6,H-5 δ 3.70, dd J H-6′,H-6 J H-6′,H-5 δ 4.79, obscured. J Hb,Ha δ 7.61–7.52, m para 6 3 δ 5.99, d J H-1,H-2 NA δ 4.52, d J H-2,H-1 δ 3.25, d J H-3,H-4 δ 4.80, t J H-4,H-3/H-5 δ 4.13, app-dddd J H-5,H-6/H-4/OH J H-5,H-6′ δ 2.90, dd J H-6′,H-6 J H-6′,H-5 δ 2.42, dd J H-6,H-6′ J H-6,H-5 δ 3.95, d J Ha,Hb J Hb,Ha δ J δ J para 7 α-fur δ 5.51, d J H-1,H-2 NA δ 4.49–4.44, m δ 4.32, dd J H-3,H-4 J H-3,H-2 δ 4.99, app-d J H-4,H-3 δ 4.49–4.44, m δ 3.65–3.60, m δ 3.57, dd J H-6′,H-6 J H-6′,H-5 δ 4.59, d J Ha,Hb J Hb,Ha δ J δ J para 7 β-fur δ 5.36, d J H-1,H-2 NA δ 4.36–4.29, obscured δ 4.22, dd J J δ 5.00, app-d J δ 4.56–4.53 δ 3.82, dd J H-6,H-6′ J H-6,H-5 δ 3.62–3.50 J H-6′,H-5 δ 4.65, d J Ha,Hb J Hb,Ha δ J δ J para 8 δ 3.55, dd J H-1,H-1′ J H-1,H-2 δ 3.25, dd J H-1′,H-1 J H-1′,H-2 δ 4.54–4.50, m δ 3.79, app-d J δ 4.40–4.34, m δ 3.82, app-dd J H-5,H-6 J H-5,H-6′ δ 4.40–4.34, m δ 3.66, dd J H-6′,H-6 J H-6′,H-5 δ 4.83, obscured. J Hb,Ha δ 7.85, dd 3 J ArH,ArH 5 J ArH,ArH 3 J ArH,ArH 5 J ArH,ArH N d 66 δ 3.64, dd J δ 3.38, dd J δ 4.54–4.47, δ 3.89–3.78, δ 4.54–4.47, δ 3.96, q J δ 3.89–3.78, m, 2H δ 4.61, d J Ha,Hb J Hb,Ha δ 7.58–7.51, m N l 67 δ 2.83, dd J H-1,H-1′ J H-1,H-2 δ 2.76, dd J H-1′,H-1 J H-1′’,H-2 δ 4.13, dt J H-2,H-1/H-1′ J H-2,H-3 δ 4.34–4.29, m δ 3.01–2.97, m δ 3.93, dt J H-5,H-6 J H-5,H-6′ δ 3.79, dd J H-6,H-6′ J H-6,H-5 δ 3.72, dd J H-6′,H-6 J H-6′,H-5 δ 3.89, d J Ha,Hb J Hb,Ha δ 7.43–7.34, m N d 68 δ 3.28, dd J H-1,H-1′ J H-1,H-2 δ 3.20, dd J H-1′,H-1 J H-1′,H-2 δ 4.21, q δ 4.11, dd J H-3,H-4 J H-3,H-2 δ 3.53, m δ 3.80, m δ 3.53, m δ 3.44, dd J H-6,H-6′ J H-6,H-5 δ 4.26, d J δ 7.30, m pharmaceuticals-18-01302-t003_Table 3 Table 3 Comparison of selected 13 N 3 5 para 6 para 8 2 J Compound: 13 2 Melting Points ° Optical Rotation C-1 C-2 C-3 C-4 C-5 C-6 ArCH 2 ArC quat ArC quat ArCHs Temp (°C) [α] D N d 64 δ 58.4, δ 70.7, δ 71.4, δ 70.3, δ 69.1, δ 63.0, δ 62.4, t δ 130.3 NA δ 130.6 NA 20 +23.1 2 N l 69 NA NA NA NA NA NA NA NA NA NA 110–111 20 −25.5 2 N d 3 65 δ 58.9 75.7 79.2 73.3 71.2 δ 63.7 δ 60.7 δ 138.6 NA δ 128.4 133–135 NA −25.5 3 N d 64 δ 59.9, t 74.8, d 76.9, d 70.0, d 68.8, d 63.6, t 61.4, t Not reported NA δ 130.5 NA 20 −31.9 2 N O d 3 3 δ 107.6 84.1 72.6 83.1 69.6 61.3 58.1 137.7 NA δ 128.9 NA 22 –14.0 3 N d 4 α-fur δ 99.0 72.6 72.2 78.8 67.4 60.5–58.8 (171 Hz) 60.0–58.2 142.4 NA δ 133.1 NA 25 0.06 N d 4 β-fur 103.2 68.6 72.8 80.7 67.5 57.5 59.8–58.8 139.4 NA 130.8 N l 5 53.1 68.9 70.2 70.1 68.6 63.1 61.6 Not NA 131.0 NA 25 −0.04 para 6 3 107.6 84.0 72.5 83.1 69.6 61.2 58.1 140.8 not 135.0 NA 25 0.13 para 7 α-fur 99.0 72.6 72.3 78.8 67.5 60.5–58.8 58.8–58.1 143.0 not 134.3 NA 19 +0.15 para 7 β-fur 103.2 72.3 72.9 80.7 67.4 60.5–58.8 Not not 134.5 para 8 53.2 68.9 70.3 70.3 63.1 61.5 134.5 not 134.3 NA 19 −0.03 2 N d 66 55.2 68.4 70.9 67.7 68.5 62.6 58.3 131.0 NA 130.4 NA 26 −25.2 3 N l 67 55.8 70.0 72.8 66.3 71.2 63.7 59.7 137.1 NA 130.3 108–109 21 +37.7 2 N d 68 56.0, t 70.7 73.9 70.6 73.4 64.5, t 63.6, t 130.9 NA 130.4 NA 20 −10.1 2 2.3.2. Electronic Effects of B on the Aromatic Ring Table 2 Table 3 Boron ester and boronic acid groups (trigonal planar geometry) on aromatic ring are slightly electron-withdrawing, due to B’s Lewis acidity, not its electronegativity, as it is less electronegative than the C atom. This can be seen when comparing aromatic chemical shifts in the 1 13 Comparison of Compounds 3 para 6 In the 13 quat 3 ortho meta para 6 It is possible to see a deshielding effect in the ortho para In the 1 3 para 6 ortho Comparison of Compounds 4 para 7 In the α-fur 13 quat 4 ortho meta para 7 In the 1 4 para 7 ortho In the β-fur 13 quat 4 ortho meta para 7 In the 1 4 para 7 ortho Comparison of Compounds 5 para 8 In the 13 para 8 5 5 ortho meta para 8 In the 1 5 para 8 ortho 2.4. 1 13 A suite of 1D- and 2D-NMR spectra was collected for detailed characterisation of intermediates 3 4 para 6 para 7 5 para 8 Supplementary Information NMR analysis of borylated compounds para 6 para 7, para 8 11 Figure S8 11 Figure S9 11 Figure S13 11 Table 1 11 70 71 72 73 47 48 49 50 51 52 3 3 11 74 74 75 11 15 Table S1 48 49 9 ortho meta para 76 10 2 11 11 77 78 79 80 High Fsp 3 16 17 Table S1 16 17 47 para 6 8 3 Comparisons for all compounds in Table 1 51 2.4.1. NMR Analysis of N d 4 Figures S2–S5 The NMR spectra show two major species, the α-fur β-fur α-fur Supporting Information Aromatic region α-fur β-fur α-fur β-fur α-fur β-fur Sugar region The α-fur J cis J β-fur J H a b a H b 2D-NMR. H a b a H b The β-fur H a b α-fur H a b α-fur H a b a H b 2D-NMR. H a b a H b 2.4.2. NMR Analysis of N l 5 Figures S6 and S7 Some highlights from the 1 5 s 2.4.3. NMR Analysis of N O d para 6 Figure S8 Scheme 2 Table 4 The elucidation of this structure was carried out as usual via 1D and 2D NMR experiments. It is important to highlight one important aspect described below. The 1 para 6 para 6 para 11 The presence of two signals points to an equilibrium between the trigonal planar B atom and several slightly quaternised B species visible on the NMR timescale. The integration between these two signals is ~3.7:1.0. This is reflected in the 1 para 6 para tet Scheme 2 3 The signal at 22 ppm could arise from an interaction between the aromatic π-system of para 6 Scheme 2 11 81 82 11 p p - + This way there would be a circular shift of electron density from the π-system of the aromatic ring to the σ* orbital of the C-D bond, from the D to the Cl atoms via the s-system, from the Cl to the B via the lone pair/empty p When MeOD is the NMR solvent, it is possible to see two signals at 32.0 and 18.0 ppm in integration ratios of 1.00:0.06. The signal at 18.0 ppm is ascribed to the para tet 3 p 2.4.4. NMR Analysis of N d para 7 Figures S9–S12 This intermediate is an equilibrium mixture of two predominant conformations, the α-fur β-fur 11 1 11 Figure S9 fur β-fur α-fur β-fur Supporting Information Aromatic region α-fur β-fur 11 Figure S9 The α-fur The COSY correlations between the two doublets of the β-fur α-fur Sugar region The α-fur J cis J β-fur J H a b a H b 2D-NMR. H a b a H b The β-fur H a b a H b J α-fur H a b a H b 2D-NMR. H a b a H b 2.4.5. NMR Analysis of N-(4-Methylphenyl boronic acid)-1,4-dideoxy-1,4-imino- l para 8 Figures S13–S16 Target molecule para 8 para 8 para 8 Aromatic region. 1 para 8 Sugar region. para 7 2 a H b H a b The doublet at 3.79 ppm was designated as H-3. At 4.40–4.34 ppm, there is a multiplet integrating to two H nuclei with correlations to signals at 3.82 and 3.66 ppm. These signals were assigned as H-6 and H-4. The dd at 3.82 ppm correlates to 4.40–4.34 and 3.66 ppm. It was assigned as H-5. The last signal, located at 3.66 ppm, was assigned as H-6′. The coupling constants are as follows: ArC H a b a H b J 2D-NMR. quat 1 H a b a H b 2 The ArC quat The principal other C nuclei signals visible are located at δ C 3. Materials and Methods 3.1. Biological Assays 3.1.1. Glycosidase Inhibition In the literature, glycosidase inhibition data are available for the following N Table 5 N d 69 l N d l d d d N N d 65 d 50 d N d 66 83 84 N 83 d d d N 66 N d d d d d d d d d d d l d E. coli l P. decumbens A. niger 66 d 83 d 50 −3 50 −4 84 N d 85 d E. coli d d N d E. coli d d 85 HIV replication inhibition by N 45 Glycosidase Inhibitions ( Table 6 Controls l 10 10 10 47 48 Glycosidase Inhibitions para 6 5 3 para 7 d para 7 d 33 Inhibition of β- d 4 para 7, para 8 50 4 para 7 para 8 d d 86 87 88 d d 89 Glycosidase Inhibitions ( Table 7 Controls 10 Figure 2 10 Figure 2 Glycosidase Inhibitions para 7, d 4 3.1.2. Cancer Screening ( Table 8 Two assays were run: the dose screen to ascertain cell growth inhibition in response to 25 µM of drug (on a blue background) and the dose response (GI 50 47 Controls Cancer Screening para 7 3 4 5 para 6 para 7 para 8 para 7 Beyond the inhibition and dose response capabilities, the real therapeutic potential of these borylated drugs lies in their switch-on/switch-off activation under BNCT radiotherapeutic conditions. This is when they become destructive to the cancer molecules, provided they can selectively accumulate in them versus healthy cells. We have demonstrated in earlier work that this is possible [ 48 90 91 pharmaceuticals-18-01302-t008_Table 8 Table 8 Cancer Screening. On blue background DOSE SCREEN: Percentage (%) Cell Growth Inhibition in response to 25 µM of Drug ( The higher the value the greater the growth inhibition 50 The lower the value, the greater the growth inhibition . * n = 3–4, otherwise n = 2 Compound HT29 U87 MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA-Pa-Ca2 MCF10A  Colon Carcinoma  Glioblastoma  Breast Carcinoma  Ovarian Carcinoma  Lung Carcinoma  Skin Carcinoma  Prostate Carcinoma  Neuroblastoma  Glioblastoma  Pancreatic Carcinoma  Breast (Normal)  BSH * 3 ± 2 * <0 * 15 ± 3 * 2 ± 5 * 8 ± 2 * <0 * 0 ± 8 * 10 ± 6 * 3 ± 8 * 2 ± 6 * 8 ± 3  10 * 5 ± 1 * 0 ± 2 * 5 ± 3 * 5 ± 4 * 4 ± 2 * <0 *7 ± 7 * 8 ± 7 * 1 ± 9 * 2 ± 4 * 13 ± 4  BPA * 14 ± 0 * <0 * <0 * 4 ± 1 * 7 ± 8 * 4 ± 6 * 19 ± 10 * 13 ± 10 * 5 ± 8 * 3 ± 3 * 4 ± 1  10 * 15 ± 4 * <0 * 1 ± 3 * 8 ± 4 * 8 ± 5 * 4 ± 4 * 15 ± 9 * 10 ± 6 * 5 ± 10 * 11 ± 3 * <0  3 * 10 ± 0 * 5 ± 4 * 7 ± 2 * 11 ± 3 * 9 ± 3 * 7 ± 4 * <0 * 10 ± 6 * 10 ± 10 * 7 ± 5 * 9 ± 4  4 * 11 ± 3 * 8 ± 4 * 9 ± 5 * 15 ± 4 * 8 ± 5 * 11 ± 5 * 0 ± 9 * 12 ± 6 * 12 ± 10 * 8 ± 6 * 14 ± 4  5 2 ± 3 NA NA  13 ± 6 * 0 ± 1 * 2 ± 4 NA NA NA 6 ± 1 * 3 ± 2  5 >50 NA NA >50 >50 >50 NA NA NA >50 >50  para 6 * 8 ± 5 * 7 ± 4 * 3 ± 4 * 14 ± 4 * 10 ± 4 * 6 ± 7 * <0 * 5 ± 4 * 9 ± 7 * 9 ± 5 * 14 ± 4  para 7  15 ± 3 NA NA   27 ± 2 9 ± 6 9 ± 5 NA NA NA  14 ± 0 4 ± 2  para 7 >50 NA NA >50 >50 >50 NA NA NA >50 >50  para 8 5 ± 2 NA NA  14 ± 7 1 ± 2 0 ± 5 NA NA NA  11 ± 1 1 ± 0  para 8 >50 NA NA >50 >50 >50 NA NA NA >50 >50 3.2. Inhibition Experimental 3.2.1. Glycosidase Inhibition Experimental ( Table 6 The enzymes α- d d d d d d l Penicillium decumbens l d E. coli A. niger para Brush border membranes were prepared from the rat small intestine according to the method of Kessler et al. [ 92 A. niger g d para 2 3 para 3.2.2. Glycosidase Inhibition Experimental ( Table 7 All enzymes and para para 3.2.3. Cancer Screening Experimental ( Table 8 All test agents were prepared as stock solutions (20 mM) in dimethyl sulfoxide (DMSO) and stored at −20 °C. Cell lines used in the study included HT29, (colorectal carcinoma); U87, SJ-G2, (glioblastoma); MCF-7, (breast carcinoma); A2780 (ovarian carcinoma); H460 (lung carcinoma); A431 (skin carcinoma); Du145 (prostate carcinoma); BE2-C (neuroblastoma) and MiaPaCa-2 (pancreatic carcinoma); together with the one non-tumour derived normal breast cell line (MCF10A). All cell lines were incubated in a humidified atmosphere 5% CO 2 −1 −1 l The non-cancer MCF10A cell line was maintained in DMEM/F12 (1:1) cell culture media, 5% heat inactivated horse serum, supplemented with penicillin (50 IUmL −1 −1 l −1 −1 −1 −1 Growth inhibition was determined by plating cells in duplicate in medium (100 µL) at a density of 2500–4000 cells per well in 96-well plates. On day 0 (24 h after plating), when the cells are in logarithmic growth, medium (100 µL) with or without the test agent was added to each well. After a 72-h drug exposure, growth inhibitory effects were evaluated using the MTT (3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and absorbance read at 540 nm. The percentage growth inhibition was calculated at a fixed concentration of 25 µM, based on the difference between the optical density values on day 0 and those at the end of drug exposure. Each data point is the mean ± the standard error of the mean (SEM) calculated from three replicates, which were performed on separate occasions and separate cell line passages. 3.2.4. Numbering System Spectroscopic data for all compounds are assigned based on a numbering system derived from systematic naming of materials according to IUPAC recommendations on carbohydrate nomenclature [ 93 Figure 1 Table 1 3.2.5. General Chemical Characterisation Experimental Spectra were recorded on a Bruker Ascend TM J 3 1 13 1 94 Supplementary Information 95 11 96 97 98 99 Infrared (IR) Spectroscopy: IR spectra were obtained on a PerkinElmer Spectrum Two Spectrometer and on a PerkinElmer Spectrum 2 with UATR. Only characteristic peaks are quoted and in units of cm −1 Low Resolution Mass Spectrometry (LRMS) spectra were obtained on an Agilent Technologies 1260 Infinity UPLC system with a 6120 Quadrupole LC/MS in electrospray ionization (ESI) positive and negative modes. All LCMS methods used a mobile phase A of 100% water with 0.1% formic acid and a mobile phase B of 9:1 v v Optical rotations were carried out on a Jasco P-2000 polarimeter with a length of 1.0 dm. Concentrations are quoted in g/100 mL. Melting points were taken on a Dynalon SMP100 Digital Melting Point Device and are uncorrected. 3.2.6. Reagents and Solvents Solvents: Dichloromethane, N N TM Reagents: Reactions performed in dry conditions and under an atmosphere of nitrogen or hydrogen were maintained by an inflated balloon. p Purification via silica gel column chromatography was performed on Davisil 40–63-micron silica gel. Thin layer chromatography (t.l.c.) was performed on aluminium sheets coated with 60 F254 silica by Merck and visualised using UVG-11 Compact UV lamp (254 nm) or stained with a solution of 12 g ammonium molybdate and 0.5 g ceric ammonium molybdate in 15 mL concentrated sulfuric acid and 235 mL distilled water. 3.3. Chemistry Experimental 3.3.1. N O d 3 3,6-Dideoxy-3,6-imino-1,2- O d p 2 2 3 f f 3 N O d 3 m z + + + + + 289 23 max −1 H 3 J H-1,H-2 J H-4,H-3/H-5 J H-2,H-1 J H-5,H-6/H-4/OH J H-5,H-6′ J Ha,Hb H a b J Hb,Ha a H b J H-3,H-4 J H-6,H-6′ J H-6,H-5 J OH,H-5 J H-6′,H-6 J H-6′,H-5 3 c 3 quat quat 2 3 3.3.2. N d 4 N O d 3 f f N d 4 m z + + + + + 289 25 max −1 H 2 α-fur β-fur Open-chain (only selected signals): Major species ( α-fur H J H-1,H-2 J J Ha,Hb H a b J Hb,Ha a H b J H-3,H-4 J H-3,H-2 J H-6′,H-6 J H-6′,H-5 c 2 quat 2 Minor species ( β-fur H J H-1,H-2 J H-4,H-3 J Ha,Hb H a b J Hb,Ha a H b J H-3,H-4 J H-3,H-2 J H-6,H-6′ J H-6,H-5 c 2 quat 2 3.3.3. N l 5 N d 4 4 4 f f 2 4 N l 5 + + + + + 289 25 max −1 H 2 H a b J H-2,H-1′ J H-2,H-1/H-3 J J H-3,H-2 J H-3,H-4 J J H-5,H-4 J H-5,H-6′ J H-5,H-6 J Hb,Ha a H b J H-6,H-6′ J H-6,H-5 J H-4,H-5′ J H-4,H-3 J H-6′,H-6 J H-6′,H-5 J H-1,H-1′ J H-1,H-2 J H-1′,H-1 J H-1′,H-2 c 3 2 quat 3.3.4. N O d para 6 3,6-Dideoxy-3,6-imino-1,2- O d p 5 2 3 f f 3 N O d para 6 m z + + + + + 289 25 max −1 para para H 3 J J J H-1,H-2 J H-4,H-3/H-5 J H-2,H-1 J H-5,H-6/H-4/OH J H-5,H-6′ J Ha,Hb H a b J Hb,Ha a H b J H-3,H-4 J H-6,H-6′ J H-6,H-5 J OH,H-5 J H-6′,H-6 J H-6′,H-5 3 3 3 c 3 quat quat quat 2 3 3 2 quat B 3 3.3.5. N d para 7 N O d para 6 f f N d para 7 m z + + + + + 289 19 max −1 para para α-fur β-fur α-fur H 2 J J J H-1,H-2 J H-4,H-3 J Ha,Hb H a b J Hb,Ha a H b J H-3,H-4 J H-3,H-2 J H-6′,H-6 J H-6′,H-5 c 2 quat 2 quat Minor species ( β-fur H 2 J J J H-1,H-2 J J Ha,Hb H a b J Hb,Ha a H b J J J H-6,H-6′ J H-6,H-5 J H-6′,H-5 c 2 2 quat quat δ B 2 3.3.6. N l para 8 N d para 7 4 4 f f N l para 8 + + + + + 289 19 2 max −1 para H 2 3 J ArH,ArH 5 J ArH,ArH 3 J ArH,ArH 5 J ArH,ArH H a b J Hb,Ha a H b J H-5,H-6 J H-5,H-6′ J J H-6′,H-6 J H-6′,H-5 J H-1,H-1′ J H-1,H-2 J H-1′,H-1 J H-1′,H-2 The main discernible boronate anion and/or boronic acid signals can be found at δ H: J J J J J H a b J a H b c 2 quat 2 quat C δ B 2 4. Conclusions The synthesis, spectroscopic, and biological investigation of five-membered ring iminosugars bearing an organic boron pharmacophore is reported. This is an important novel class of iminosugars capable of establishing not only the traditional intermolecular interactions with enzyme active sites, but are also imbued with the capability of reversible intramolecular interactions via dative bonding from nucleophilic amino acid side chains and the boron atom’s empty p N 50 d d Disclaimer/Publisher’s Note: Supplementary Materials The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph18091302/s1 11 1 13 N O d 3 3 1 13 N d 4 2 1 2 N d 4 α-fur β-fur 1 2 N d 4 α-fur β-fur 13 2 N d 4 α-fur β-fur 1 13 N l 5 2 1 2 N l 5 1 13 11 N O d para 6 3 1 13 11 N d para 7 2 1 2 N d para 7 α-fur β-fur 1 2 N d para 7 α-fur β-fur 13 2 N d para 7 α-fur β-fur 1 13 11 N l para 8 2 1 2 N l para 8 1 2 N l para 8 13 2 N l para 8 47 48 49 52 100 Author Contributions Manuscript conception, M.S.; writing and original draft preparation, M.S.; synthesis and characterization of derivatives, M.S., K.P.; biological assays, A.K., R.N., J.S., S.Y., Y.S., K.Y., B.B., J.G.; editing, data analysis, and interpretation, M.S., A.K., R.N., J.S. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement Not applicable. Informed Consent Statement Not applicable. Data Availability Statement The data presented in this study are available on request from the corresponding author. Conflicts of Interest Authors B.B. and R.N. were employed by the company PhytoQuest Ltd. The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. References 1. Lowering F. Bikker J. Humblet C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success J. Med. Chem. 2009 52 6752 6756 10.1021/jm901241e 19827778 2. Petri G.L. Raimondi M.V. Spanò V. Holl R. Barraja P. Montalbano A. Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds Topics Curr. Chem. 2021 379 34 80 10.1007/s41061-021-00347-5 PMC8352847 34373963 3. Compain P. Martin O.R. Iminosugars: From Synthesis to Therapeutic Applications John Wiley & Sons, Ltd. Chichester, UK 2007 4. Derosa G. Maffioli P. α-Glucosidase inhibitors and their use in clinical practice Arch. Med. Sci. 2012 8 899 906 10.5114/aoms.2012.31621 23185202 PMC3506243 5. Sohrabi M. Binaeizadeh M.R. Iraji A. Larijani B. Saeedi M. Mahdavi M. A review on α-glucosidase inhibitory activity of first row transition metal complexes: A futuristic strategy for treatment of type 2 diabetes RSC Adv. 2022 12 12011 12052 10.1039/D2RA00067A 35481063 PMC9020348 6. Akmal M. Wadhwa R. Alpha Glucosidase Inhibitors Available online: https://www.ncbi.nlm.nih.gov/books/NBK557848/ (accessed on 9 May 2025) 32496728 7. Liu S.K. Hao H. Bian Y. Ge Y.X. Lu S. Xie H.X. Wang K.M. Tao H. Yuan C. Zhang J. Discovery of New α-Glucosidase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation Front. Chem. 2021 9 639279 10.3389/fchem.2021.639279 33763406 PMC7982526 8. Yen F.S. Wei J.C.C. Lin M.C. Hsu C.C. Hwu C.M. Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes BMC Endocr. Dis. 2021 21 25 10.1186/s12902-021-00690-0 PMC7890630 33602190 9. Tsunoda T. Samadi A. Burade S. Mahmud T. Complete biosynthetic pathway to the antidiabetic drug acarbose Nat. Commun. 2022 13 3455 10.1038/s41467-022-31232-4 35705566 PMC9200736 10. Platt F.M. d’Azzo A. Davidson B.L. Neufeld E.F. Tifft C.J. Lysosomal storage diseases Nat. Rev. Dis. Primers 2018 4 27 10.1038/s41572-018-0025-4 30275469 11. Aerts J.M.F.G. Kuo C.L. Lelieveld L.T. Boer D.E.C. Lienden M.J.C.V.D. Overkleeft H.S. Artola M. Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease Curr. Opin. Chem. Biol. 2019 53 204 215 10.1016/j.cbpa.2019.10.006 31783225 12. Sánchez-Fernández E.M. Fernández J.M.G. Mellet C.O. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: Lessons from Gaucher, GM1-gangliosidosis and Fabry diseases Chem. Commun. 2016 52 5497 5515 10.1039/C6CC01564F 27043200 13. Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: From concept to clinics EMBO Mol. Med. 2009 1 268 279 10.1002/emmm.200900036 20049730 PMC3378140 14. Pastores G.M. Hughes D.A. Lysosomal Storage Disorders and Malignancy Diseases 2017 5 8 10.3390/diseases5010008 28933361 PMC5456337 15. Mashima R. Okuyama T. Ohira M. Biomarkers for Lysosomal Storage Disorders with an Emphasis on Mass Spectrometry Int. J. Mol. Sci. 2020 21 2704 10.3390/ijms21082704 32295281 PMC7215887 16. Esposito A. D’Alonzo D. Fenza M.D. Gregorio E.D. Tamanini A. Lippi G. Dechecchi M.C. Guaragna A. Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis Int. J. Mol. Sci. 2020 21 3353 10.3390/ijms21093353 32397443 PMC7247015 17. Best D. Jenkinson S.F. Saville A.W. Alonzi D.S. Wormald M.R. Butters T.D. Norez C. Becq F. Blériot Y. Adachi I. Cystic fibrosis and diabetes: isoLAB and isoDAB, enantiomeric carbon-branched pyrrolidine iminosugars Tetrahedron Lett. 2010 51 4170 4174 10.1016/j.tetlet.2010.05.131 18. Pucci M. Duca M. Malagolini N. Dall’Olio F. Glycosyltransferases in Cancer: Prognostic Biomarkers of Survival in Patient Cohorts and Impact on Malignancy in Experimental Models Cancers 2022 14 2128 10.3390/cancers14092128 35565254 PMC9100214 19. Marimuthu S. Batra S.K. Ponnusamy M.P. Pan-cancer analysis of altered glycosyltransferases confers poor clinical outcomes Clin. Transl. Disc. 2022 2 e100 e105 10.1002/ctd2.100 PMC9302706 35875597 20. Costa A.F. Campos D. Reis C.A. Gomes C. Targeting Glycosylation: A New Road for Cancer Drug Discovery Trends Cancer 2020 6 757 766 10.1016/j.trecan.2020.04.002 32381431 21. Du Y. Ye H. Gill T. Wang L. Guo F. Cuconati A. Guo J.T. Block T.M. Chang J. Xu X. N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections Bioorg. Med. Chem. Lett. 2013 23 2172 2176 10.1016/j.bmcl.2013.01.108 23453839 22. Simone M. Soengas R.G. Jenkinson S.F. Evinson E.L. Nash R.J. Fleet G.W.J. Synthesis of three branched iminosugars [(3R,4R,5S)-3-(hydroxymethyl)piperidine-3,4,5-triol, (3R,4R,5R)-3-(hydroxymethyl)piperidine-3,4,5-triol and (3S,4R,5R)-3-(hydroxymethyl)piperidine-3,4,5-triol] and a branched trihydroxynipecotic acid [(3R,4R,5R)-3,4,5-trihydroxypiperidine-3-carboxylic acid] from sugar lactones with a carbon substituent at C-2 Tetrahedron Asymm. 2012 23 401 408 10.1016/j.tetasy.2012.03.007 23. Liang P.H. Cheng W.C. Lee Y.L. Yu H.P. Wu Y.T. Lin Y.L. Wong C.H. Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis ChemBioChem 2006 7 165 173 10.1002/cbic.200500321 16397876 PMC7161998 24. Ma J. Zhang X. Soloveva V. Warren T. Guo F. Wu S. Lu H. Guo J. Su Q. Shen H. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo Antivir. Res. 2018 150 112 122 10.1016/j.antiviral.2017.12.008 29253498 PMC5800948 25. Yu W. Gill T. Wang L. Du Y. Ye H. Qu X. Guo J.T. Cuconati A. Zhao K. Block T.M. Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection J. Med. Chem. 2012 55 6061 6075 10.1021/jm300171v 22712544 PMC3395807 26. Fischer P.B. Collin M. Karlsson G.B. James W. Butters T.D. Davis S.J. Gordon S. Dwek R.A. Platt F.M. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding J. Virol. 1995 69 5791 5797 10.1128/jvi.69.9.5791-5797.1995 7543588 PMC189444 27. Terrault N.A. Benefits and risks of combination therapy for hepatitis B Hepatology 2009 49 S122 S128 10.1002/hep.22921 19399796 28. Miller J.L. Lachica R. Sayce A.C. Williams J.P. Bapat M. Dwek R. Beatty P.R. Harris E. Zitzmann N. Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo Antimicrob. Agents Chemother. 2012 56 6379 6386 10.1128/AAC.01554-12 23070155 PMC3497178 29. Li Y. Xu S. Ye Q. Chi H. Guo Z. Chen J. Wu M. Fan B. Li B. Qin C.F. Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants Adv. Sci. 2022 10 2202689 10.1002/advs.202202689 PMC9839850 36377484 30. Dwek R.A. Butters T.D. Platt F.M. Zitzmann N. Targeting Glycosylation as a Therapeutic Approach Nat. Rev. Drug Disc. 2002 1 65 75 10.1038/nrd708 12119611 31. Chang J. Block T.M. Guo J.T. Antiviral therapies targeting host ER α-glucosidases: Current status and future directions Antivir. Res. 2013 99 251 260 10.1016/j.antiviral.2013.06.011 23816430 PMC7114303 32. Chang J. Schul W. Butters T.D. Yip A. Liu B. Goh A. Lakshminarayana S.B. Alonzi D. Reinkensmeier G. Pan X. Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo Antivir. Res. 2011 89 26 34 10.1016/j.antiviral.2010.11.002 21073903 PMC3018560 33. Prichard K. Campkin D. O’Brien N. Kato A. Fleet G.W.J. Simone M. Biological Activities of 3,4,5-Trihydroxypiperidines and their O N Chem. Biol. Drug Des. 2018 92 1171 1197 10.1111/cbdd.13182 29469975 34. Clemente F. Matassini C. Cardona F. Reductive Amination Routes in the Synthesis of Piperidine Imino Sugars Eur. J. Org. Chem. 2020 2020 4447 4462 10.1002/ejoc.201901840 35. Parmeggiani C. Catarzi S. Matassini C. D’Adamio G. Morrone A. Goti A. Paoli P. Cardona F. Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease ChemBioChem 2015 16 2054 2064 10.1002/cbic.201500292 26376302 36. Wang Y. Xiao J. Meng A. Liu C. Multivalent Pyrrolidine Iminosugars: Synthesis and Biological Relevance Molecules 2022 27 5420 10.3390/molecules27175420 36080188 PMC9457877 37. Denavit V. St-Gelais J. Tremblay T. Giguère D. Exploring the Chemistry of Non-sticky Sugars: Synthesis of Polyfluorinated Carbohydrate Analogues of D-Allopyranose Chem. Eur. J. 2019 25 9272 9279 10.1002/chem.201901346 31099933 38. Conforti I. Marra A. Iminosugars as glycosyltransferase inhibitors Org. Biomol. Chem. 2021 19 5439 5475 10.1039/D1OB00382H 33881114 39. Horne G. Iminosugars: Therapeutic Applications and Synthetic Considerations Topics in Medicinal Chemistry 12 Seeberger P. Rademacher C. Springer Cham, Switzerland Berlin/Heidelberg, Germany New York, NY, USA Dordrecht, The Netherlands London, UK 2014 23 51 40. Nash R.J. Kato A. Yu C.Y. Fleet G.W.J. Iminosugars as therapeutic agents: Recent advances and promising trends Future Med. Chem. 2011 3 1513 1521 10.4155/fmc.11.117 21882944 41. Bhushan G. Lim L. Bird I. Chothe S.K. Nissly R.H. Kuchipudi S.V. Iminosugars with Endoplasmic Reticulum α-Glucosidase Inhibitor Activity Inhibit ZIKV Replication and Reverse Cytopathogenicity in vitro Front. Microbiol. 2020 11 531 546 10.3389/fmicb.2020.00531 32373079 PMC7179685 42. Zamoner L.O.B. Aragão-Leoneti V. Carvalho I. Iminosugars: Effects of Stereochemistry, Ring Size, and N-Substituents on Glucosidase Activities Pharmaceuticals 2019 12 108 10.3390/ph12030108 31336868 PMC6789487 43. Wood A. Prichard K.L. Clarke Z. Houston T.A. Fleet G.W.J. Simone M. Synthetic Pathways to 3,4,5-Trihydroxypiperidines from the Chiral Pool Eur. J. Org. Chem. 2018 2018 6812 6829 10.1002/ejoc.201800943 44. Winkler D.A. Holan G. Design of Potential Anti-HIV Agents. 1. Mannosidase Inhibitors J. Med. Chem. 1989 32 2084 2089 10.1021/jm00129a011 2504921 45. Fleet G.W.J. Karpas A. Dwek R.A. Fellows L.E. Tyms A.S. Petursson S. Namgoong S.K. Ramsden N.G. Smith P.W. Son J.C. Inhibition of HIV replication by amino-sugar derivatives FEBS Lett. 1988 237 128 132 10.1016/0014-5793(88)80185-6 3169233 46. Simone M. Edwards A.A. Tranter G.E. Fleet G.W.J. C-3 Branched δ-3,5-cis- and trans-THF Sugar Amino Acids: Synthesis of the first generation of branched homooligomers Amino Acids 2011 41 643 661 10.1007/s00726-011-0849-7 21350854 47. Simone M. Diastereoselective Synthesis of the Borylated D-Galactose Monosaccharide 3-Boronic-3-Deoxy- d Molecules 2023 28 4321 10.3390/molecules28114321 37298796 PMC10254170 48. Campkin D.M. Shimadate Y. Bartholomew B. Bernhardt P.V. Nash R.J. Sakoff J.A. Kato A. Simone M. Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy Molecules 2022 27 3447 10.3390/molecules27113447 35684388 PMC9182199 49. Legge W.J. Shimadate Y. Sakoff J. Houston T.A. Kato A. Bernhardt P.V. Simone M. Borylated methyl cinnamates: Green synthesis, characterization, crystallographic analysis and biological activities–in glycosidase inhibition and in cancer cells lines Beilstein Arch. 2021 20214 10.3762/bxiv.2021.4.v1 50. Jenkinson S.F. Thompson A.L. Simone M. Methyl 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-4-nitrobenzoate Acta Cryst. 2012 68 o2429 o2430 10.1107/S1600536812029650 PMC3414346 22904879 51. Simone M. Borylated 5-Membered Ring Iminosugars: Detailed Nuclear Magnetic Resonance Spectroscopic Characterisation, and Method for Analysis of Anomeric and Boron Equilibria Molecules 2025 30 1402 10.3390/molecules30071402 40285852 PMC11990579 52. Simone M. Borylated Monosaccharide 3-Boronic-3-deoxy- d Int. J. Mol. Sci. 2024 25 12396 10.3390/ijms252212396 39596462 PMC11594630 53. Deng J.P. Yu C.S. Recent Development of Radiofluorination of Boron Agents for Boron Neutron Capture Therapy of Tumor: Creation of 18 Pharmaceuticals 2023 16 93 10.3390/ph16010093 36678590 PMC9866017 54. Barth R.F. Mi P. Yang W. Boron delivery agents for neutron capture therapy of cancer Cancer Commun. 2018 38 35 10.1186/s40880-018-0299-7 PMC6006782 29914561 55. Cheng X. Li F. Liang L. Boron Neutron Capture Therapy: Clinical Application and Research Progress Curr. Oncol. 2022 29 7868 7886 10.3390/curroncol29100622 36290899 PMC9601095 56. Austin G.N. Baird P.D. Fleet G.W.J. Peach J.M. Smith P.W. Watkin D.J. 3,6-Dideoxy-3,6-imino-1,2-O-isopropylidene-a- d l d Tetrahedron 1987 43 3095 3108 10.1016/S0040-4020(01)86851-4 57. Hall D.G. Boronic Acids: Preparation and Applications in Organic Synthesis, Medicine and Materials. Chapter 1: Structure, properties, and preparation of boronic acid derivatives Overview of Their Reactions and Applications Wiley-VCH Verlag GmbH & Co. KGaA Weinheim, Germany 2011 58. Buchner G.S. Murphy R.D. Buchete N.V. Kubelka J. Dynamics of protein folding: Probing the kinetic network of folding–unfolding transitions with experiment and theory Biochim. Biophys. Acta 2011 1814 1001 1020 10.1016/j.bbapap.2010.09.013 20883829 59. Alexandersson E. Nestor G. Complete 1 13 Carbohydr. Res. 2022 511 108477 10.1016/j.carres.2021.108477 34784518 60. Speciale I. Notaro A. Garcia-Vello P. Lorenzo F.D. Armiento S. Molinaro A. Marchetti R. Silipo A. Castro C.D. Liquid-state NMR spectroscopy for complex carbohydrate structural analysis: A hitchhiker’s guide Carbohydr. Polymers 2022 277 118885 10.1016/j.carbpol.2021.118885 34893288 61. Anet F.A.L. Anet R. Chapter 14: Conformational Processes in Rings Dynamic Nuclear Magnetic Resonance Spectroscopy Jackman L.M. Cotton F.A. Academic Press New York, NY, USA 1975 62. Angyal S.J. Pickles V.A. Equilibria between pyranoses and furanoses Aust. J. Chem. 1972 25 1695 1710 10.1071/CH9721695 63. Synytsya A. Opíková J. Brus J. 13C CP/MAS NMR Spectra of Pectins: A Peak-Fitting Analysis in the C-6 Region Czech J. Food Sci. 2003 21 1 12 10.17221/3471-CJFS 64. Fleet G.W.J. Son J.C. Polyhydroxylated pyrrolidines from sugar lactomes: Synthesis of 1,4-dideoxy-1,4-imino- d d d Tetrahedron 1988 44 2637 2647 10.1016/S0040-4020(01)81716-6 65. Guazzelli L. D’Andrea F. Sartini S. Giorgelli F. Confini G. Quattrini L. Piano I. Gargini C. Motta C.L. Synthesis and investigation of polyhydroxylated pyrrolidine derivatives as novel chemotypes showing dual activity as glucosidase and aldose reductase inhibitors Bioorg. Chem. 2019 92 103298 10.1016/j.bioorg.2019.103298 31557624 66. Yang L.F. Shimadate Y. Kato A. Li Y.X. Jia Y.M. Fleet G.W.J. Yu C.Y. Synthesis and glycosidase inhibition of N-substituted derivatives of 1,4-dideoxy-1,4-imino-d-mannitol (DIM) Org. Biomol. Chem. 2020 18 999 1011 10.1039/C9OB02029B 31944194 67. Håkansson A.E. Ameijde J.V. Guglielmini L. Horne G. Nash R.J. Evinson E.L. Kato A. Fleet G.W.J. Looking glass inhibitors: Synthesis of a potent naringinase inhibitor L-DIM [1,4-dideoxy-1,4-imino- l d d Tetrahedron Asymm. 2007 18 282 289 10.1016/j.tetasy.2007.01.010 68. Fleet G.W.J. Son J.C. Green D.S.C. Bello I.C.D. Winchester B. Synthesis from D-mannose of 1,4-dideoxy-1,4-imino- l d Tetrahedron 1988 44 2649 2655 10.1016/S0040-4020(01)81717-8 69. Daher S.A. Fleet G. Namgoong S.K. Winchester B. Change in specificity of glycosidase inhibition by N-alkylation of amino sugars Biochem. J. 1989 258 613 615 10.1042/bj2580613 2706004 PMC1138406 70. Snyder H.R. Konecky M.S. Lennarz W.J. Aryl boronic acids. ii. aryl boronic anhydrides and their amine complexes J. Am. Chem. Soc. 1958 80 3611 3615 10.1021/ja01547a033 71. Chen L. Zou X. Zhao H. Xu S. Copper-Catalyzed Asymmetric Protoboration of β-Amidoacrylonitriles and β-Amidoacrylate Esters: An Efficient Approach to Functionalized Chiral α-Amino Boronate Esters Org. Lett. 2017 19 3676 3679 10.1021/acs.orglett.7b01740 28636396 72. Touchet S. Mace A. Roisnel T. Carreaux F. Bouillon A. Carboni B. [3,3]-Sigmatropic Rearrangement of Boronated Allylcyanates: A New Route to α-Aminoboronate Derivatives and Trisubstituted Tetrahydrofurans Org. Lett. 2013 15 2712 2715 10.1021/ol401016x 23692512 73. Lai J.H. Liu Y. Wu W. Zhou Y. Maw H.H. Bachovchin W.W. Bhat K.L. Bock C.W. Synthesis and structural investigation of internally coordinated α-amidoboronic acids J. Org. Chem. 2006 71 512 519 10.1021/jo051757h 16408958 74. Wrackmeyer B. Nuclear magnetic resonance spectroscopy of boron compounds containing two-, three-and four-coordinate boron Ann. Rep. NMR Spectr. 1988 20 61 203 10.1016/S0066-4103(08)60170-2 75. Weiss J.W. Bryce D.L. A solid-state 11 J. Phys. Chem. A 2010 114 5119 5131 10.1021/jp101416k 20337440 PMC2857870 76. Zhuo J.C. Soloway A.H. Beeson J.C. Ji W. Barnum B.A. Rong F.G. Tjarks W. Jordan G.T. Liu J. Shore S.G. Boron-containing heterocycles: Syntheses, structures, and properties of benzoborauracils and a benzoborauracil nucleoside J. Org. Chem. 1999 64 9566 9574 10.1021/jo991176q 77. 11B-NMR Chemical Shifts Available online: https://www.chemistry.sdsu.edu/research/BNMR/ (accessed on 17 December 2023) 78. Nanalysis Boron NMR Spectroscopy Available online: https://www.nanalysis.com/nmready-blog/2016/10/17/boron-nmr-spectroscopy (accessed on 17 December 2023) 79. Wrackmeyer B. Organoboranes and tetraorganoborates studied by 11 13 Z. Naturforsch. 2015 70 421 424 10.1515/znb-2015-0040 80. León-Negrete A. Villamil-Ramos R. Sánchez-Portillo P. González-Hernández A. Barba V. Six-Membered Heterocyclic Boronate Esters. Synthesis and Structural Analysis J. Mex. Chem. Soc. 2022 66 421 432 10.29356/jmcs.v66i4.1718 81. Tsuzuki S. Honda K. Uchimaru T. Mikami M. Tanabe K. The interaction of benzene with chloro-and fluoromethanes: Effects of halogenation on CH/π interaction J. Phys. Chem. A 2002 106 4423 4428 10.1021/jp013723t 82. Tamres M. Aromatic Compounds as Donor Molecules in Hydrogen Bonding J. Am. Chem. Soc. 1952 74 3375 3378 10.1021/ja01133a047 83. Winchester B. Daher S.A. Carpenter N.C. Bello I.C.D. Choi S.S. Fairbanks A.J. Fleet G.W.J. The structural basis of the inhibition of human α-mannosidases by azafuranose analogues of mannose Biochem. J. 1993 290 743 749 10.1042/bj2900743 8457203 PMC1132343 84. Šesták S. Bella M. Klunda T. Gurská S. Dzubáck P. Wöls F. Wilson I.B.H. Sladek V. Hajdúch M. Poláková M. N-Benzyl Substitution of Polyhydroxypyrrolidines: The Way to Selective Inhibitors of Golgi a-Mannosidase II ChemMedChem 2018 13 373 383 10.1002/cmdc.201700607 29323461 PMC6176901 85. Johnson L.L. Houston T.A. A drug targeting motif for glycosidase inhibitors: An iminosugar–boronate shows unexpectedly selective β-galactosidase inhibition Tetrahedron Lett. 2002 43 8905 8908 10.1016/S0040-4039(02)02196-2 86. Cox T.M. Gaucher’s Disease Academic Press Cambridge, MA, USA 2001 87. Mena-Barragán T. García-Moreno M.I. Sevšek A. Okazaki T. Nanba E. Higaki K. Martin N.I. Pieters R.J. Fernández J.M.G. Mellet C.O. Probing the Inhibitor versus Chaperone Properties of sp 2 Molecules 2018 23 927 10.3390/molecules23040927 29673163 PMC6017062 88. Martín-Banderas L. Holgado M.A. Durán-Lobato M. Infante J.J. Álvarez-Fuentes J. Fernández-Arévalo M. Role of Nanotechnology for Enzyme Replacement Therapy in Lysosomal Diseases. A Focus on Gaucher’s Disease Curr. Med. Chem. 2016 23 929 952 10.2174/0929867323666160210130608 26860997 89. Hinek A. Zhang S. Smith A.C. Callahan J.W. Impaired Elastic-Fiber Assembly by Fibroblasts from Patients with Either Morquio B Disease or Infantile GM1-Gangliosidosis Is Linked to Deficiency in the 67-kD Spliced Variant of β-Galactosidase Am. J. Hum. Genet. 2000 67 23 26 10.1086/302968 10841810 PMC1287082 90. Glenister A. Chen C.K.J. Renfrew A.K. Simone M. Hambley T.W. Warburg Effect Targeting Cobalt(III) Cytotoxin Chaperone Complexes J. Med. Chem. 2021 64 2678 2690 10.1021/acs.jmedchem.0c01875 33621096 91. Glenister A. Simone M. Hambley T.W. A Warburg effect targeting vector designed to increase the uptake of compounds by cancer cells demonstrates glucose and hypoxia dependent uptake PLoS ONE 2019 14 e0217712 10.1371/journal.pone.0217712 31306426 PMC6629077 92. Kessler M. Acuto O. Storelli C. Murer H. Müller M. Semenza G. A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes. Their use in investigating some properties of D-glucose and choline transport systems Biochim. Biophys. Acta 1978 506 136 154 10.1016/0005-2736(78)90440-6 620021 93. McNaught A.D. IUPAC and IUBMB Joint Commission on Biochemical Nomenclature; Nomenclature of Carbohydrates Pure Appl. Chem. 1996 68 1919 2008 10.1351/pac199668101919 94. Gottlieb H.E. Kotlyar V. Nudelman A. NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities J. Org. Chem. 1997 62 7512 7515 10.1021/jo971176v 11671879 95. Bruker NMR Software TopSpin Available online: https://www.bruker.com/en/products-and-solutions/mr/nmr-software/topspin.html?utm_source=Advertising&utm_medium=GoogleAd&utm_campaign=BBIO-Software-Cross-All-TopSpin-H2-2025&gad_source=1&gad_campaignid=15149563659&gbraid=0AAAAADsq6H3hmr5YRBHOpUv-a-tmY2e0U&gclid=EAIaIQobChMIvr208NXjjgMVzy57Bx1-LwL3EAAYASAAEgKW-vD_BwE (accessed on 30 June 2025) 96. Sigma-Aldrich Available online: https://www.sigmaaldrich.com/AU/en/product/aldrich/dwk231700006?srsltid=AfmBOooBqu8eAIi5jtc28sWdih3PbRDScnsOaxbYMVB8PVNLSPe6lWxm (accessed on 20 February 2025) 97. Corning Available online: https://ecatalog.corning.com/life-sciences/b2c/US/en/General-Labware/Tubes/Tubes-Storage/PYREX®-Tube%2C-NMR%2C-5-mm-Diameter/p/pyrexTubeNMR5mmDiameter (accessed on 20 February 2025) 98. Bruker Available online: https://www.bruker.com/en/products-and-solutions/mr/nmr/nmr-probes.html (accessed on 20 February 2025) 99. Macho J.M. Blue R.M. Lee H.W. MacMillan J.B. Boron NMR as a Method to Screen Natural Product Libraries for B-Containing Compounds Org. Lett. 2022 24 3161 3166 10.1021/acs.orglett.2c00885 35472262 PMC9088847 100. Boron Molecular A Fine Chemicals Manufacturer Available online: https://www.boronmolecular.com (accessed on 21 April 2025) Figures, Schemes and Tables pharmaceuticals-18-01302-sch001_Scheme 1 Scheme 1 Reagents and reaction conditions: (i) (a) Pyridine, DCM; Tf 2 2 3 2 p 2 2 2 2 3 4 4 2 2 3 4 1 2 5 Figure 1 11 para 6 para 7 para 8 pharmaceuticals-18-01302-sch002_Scheme 2 Scheme 2 ( top p para 6 3 bottom 3 Figure 2 Structures of (left) BSH/ 10 10 pharmaceuticals-18-01302-t004_Table 4 Table 4 11 para 6 Solvent Chemical Shift, ppm Proposed Assignment CDCl 3 30 (1.00) Boronate ester (trigonal planar) 22 (0.35) Solvent CDCl 3 3 p MeOD 32 (1.00) Boronate ester (trigonal planar) 18 (0.06) Solvent MeOD → B p MeOD acidified with HCl to pH 1 29.8 (1.00) Boronate ester (trigonal planar) 19.3 (0.12) Solvent MeOD → B p pharmaceuticals-18-01302-t005_Table 5 Table 5 Summary of glycosidase inhibitions by N Iminosugar Glycosidase/s Most Inhibited N  d 69 α- l d 65 α- d 50 d - 66 83 84 α- d d 85 NI N d 85 β- d E. coli pharmaceuticals-18-01302-t006_Table 6 Table 6 Glycosidase inhibition studies. Percentage inhibition data for controls (BSH, 10 10 3 4 para 6 para 7 5 para 8 50 Compound α- d β- d α- d β- d α- d β- d α- l α- l β- d α,α- Amyloglucosidase Rice Yeast Rat Almond Bovine Liver Coffee Beans Bovine Liver Jack Bean Snail  P. decumbens Bovine  E. coli Bovine Liver Porcine  A. niger  BSH a b a b a b a b a b a b a b a b a b a b a b a b a b a b a b  10 a b a b a b a b a b a b a b a b a b a b a b a b a b a b a b  BPA c d c d c d c d c d c d c d c d c d c d c d c d c d c d c d  10 c d c d c d c d c d c d c d c d c d c d c d c d c d c d c d  3 c d c d c d c d c d c d c d c d c d c d c d c d c d c d c d  4 a b a b a b a b a b a b 133 a b a b a b a b a b a b a b a b  5 c d c d c d c d c d c d c d c d c d c d NA c d c d c d c d  para 6 c d c d c d c d c d c d c d c d c d c d c d c d c d c d c d  para 7 a b a b a b a b a b a b 218 a b a b a b a b a b a b a b a b  para 8 a b a b a b a b a b a b 501 a b a b a b a b a b a b a b a b a b c d 5 d c d d c d d E. coli c d d T. longibrachiatum c d pharmaceuticals-18-01302-t007_Table 7 Table 7 Glycosidase inhibition studies. Percentage inhibition data for controls (BSH, 10 10 3 4 para 6, para 7 5 para 8 Compound Appearance α- d β- d- α- d N d- N d β- d Yeast  Bacillus Rat Almond Jack Bean Bovine Kidney Rat Intestine Bovine Liver  BSH In solution 59 48.1 NA 47.3 −18.7 37.1 NA 31.6  10 In solution 65.9 53 NA 49.9 −16.8 40.9 NA 44.1  BPA Some in solution with undissolved sediment 2.9 19.9 NA 3.9 0.6 6.7 NA −0.7  10 Some in solution with undissolved sediment 3.4 19.5 NA 3 −0.7 6.3 NA −1  3 In solution −89 −43.2 NA −8.3 −30.6 −0.1 NA −0.2  4 In solution −79 −37.9 NA 58.1 −12.1 −9.1 NA −4.3  5 In solution 5.5 NA −1.3 17.1 NA NA −1.5 −2.2  para 6  Completely insoluble NA NA NA NA NA NA NA NA  para 7 In solution 4.2 NA −5.4 68.1 NA NA 4.4 1.1  para 8 In solution 9.7 NA ND 23.9 NA NA 2.6 2.4 ",
  "metadata": {
    "Title of this paper": "A Fine Chemicals Manufacturer",
    "Journal it was published in:": "Pharmaceuticals",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472391/"
  }
}